Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
fruquintinib + sintilimab versus investigator's choice chemotherapy for second-line advanced endometrial cancer
CTR20242784Phase 3Active
- Sponsor
- HUTCHMED
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fruquintinib, sintilimab in endometrial cancer (EC), sponsored by HUTCHMED. Started Dec 2024; status: active.
02
Drugs
fruquintinibsintilimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20242784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242784.